Tyrosine Kinase Inhibitor-induced cardiotoxicity in hiPSC derived cardiomyocytes - Proteomics

To define protein markers of tyrosine kinase inhibitor-induced cardiotoxicity, we treated human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) with tyrosine kinase inhibitors (TKIs) displaying a range of mild to severe effects on heart function. Two independent cell experiments were performed. In the first experiment, hiPSC-CMs were treated with one of four TKIs (Erlotinib, Lapatinib, Sorafenib and Sunitinib) at 3 μM or a DMSO vehicle-only control in biological replicates (10 samples in total) and harvested at 72 hours for tandem mass tag mass spectrometry. In the second experiment, a different lot of hiPSC-CMs were treated the same way, but samples were collected at both 24 and 72 hours (20 samples in total).

Corresponding gene expression data can be found in datasets 20324 and 20325.